Does the media favor TECX or ADCT?

In the previous week, Tectonic Therapeutic had 1 more articles in the media than ADC Therapeutics. MarketBeat recorded 2 mentions for Tectonic Therapeutic and 1 mentions for ADC Therapeutics. Tectonic Therapeutic's average media sentiment score of 1.61 beat ADC Therapeutics' score of 0.00 indicating that Tectonic Therapeutic is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tectonic Therapeutic 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive ADC Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ADCT or FDMT?

In the previous week, 4D Molecular Therapeutics had 1 more articles in the media than ADC Therapeutics. MarketBeat recorded 2 mentions for 4D Molecular Therapeutics and 1 mentions for ADC Therapeutics. 4D Molecular Therapeutics' average media sentiment score of 0.94 beat ADC Therapeutics' score of 0.00 indicating that 4D Molecular Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADC Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral 4D Molecular Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MNPR or ADCT?

In the previous week, Monopar Therapeutics had 2 more articles in the media than ADC Therapeutics. MarketBeat recorded 3 mentions for Monopar Therapeutics and 1 mentions for ADC Therapeutics. Monopar Therapeutics' average media sentiment score of 0.46 beat ADC Therapeutics' score of 0.00 indicating that Monopar Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monopar Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral ADC Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer CTMX or ADCT?

In the previous week, CytomX Therapeutics had 3 more articles in the media than ADC Therapeutics. MarketBeat recorded 4 mentions for CytomX Therapeutics and 1 mentions for ADC Therapeutics. CytomX Therapeutics' average media sentiment score of 1.18 beat ADC Therapeutics' score of 0.00 indicating that CytomX Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CytomX Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ADC Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

ADC Therapeutics (ADCT) Competitors

$1.24 -0.05 (-3.95%)

Closing price 07/13/2026 03:59 PM Eastern

Extended Trading

$1.24 0.00 (-0.32%)

As of 08:01 AM Eastern

Compare

ADCT vs. TECX, FDMT, MNPR, RLMD, and CTMX

Should you buy ADC Therapeutics stock or one of its competitors? MarketBeat compares ADC Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ADC Therapeutics include Tectonic Therapeutic (TECX), 4D Molecular Therapeutics (FDMT), Monopar Therapeutics (MNPR), Relmada Therapeutics (RLMD), and CytomX Therapeutics (CTMX). These companies are all part of the "pharmaceutical products" industry.

How does ADC Therapeutics compare to Tectonic Therapeutic?

Tectonic Therapeutic (NASDAQ:TECX) and ADC Therapeutics (NYSE:ADCT) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, media sentiment, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.

Tectonic Therapeutic has higher earnings, but lower revenue than ADC Therapeutics. Tectonic Therapeutic is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tectonic Therapeutic	N/A	N/A	-$74.15M	-$4.46	N/A
ADC Therapeutics	$81.36M	1.94	-$142.62M	-$1.05	N/A

Tectonic Therapeutic has a net margin of 0.00% compared to ADC Therapeutics' net margin of -173.02%. ADC Therapeutics' return on equity of 0.00% beat Tectonic Therapeutic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tectonic Therapeutic	N/A	-32.33%	-30.92%
ADC Therapeutics	-173.02%	N/A	-44.70%

In the previous week, Tectonic Therapeutic had 1 more articles in the media than ADC Therapeutics. MarketBeat recorded 2 mentions for Tectonic Therapeutic and 1 mentions for ADC Therapeutics. Tectonic Therapeutic's average media sentiment score of 1.61 beat ADC Therapeutics' score of 0.00 indicating that Tectonic Therapeutic is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tectonic Therapeutic	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
ADC Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

62.6% of Tectonic Therapeutic shares are held by institutional investors. Comparatively, 41.1% of ADC Therapeutics shares are held by institutional investors. 39.8% of Tectonic Therapeutic shares are held by insiders. Comparatively, 5.4% of ADC Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Tectonic Therapeutic has a beta of 3.21, indicating that its stock price is 221% more volatile than the broader market. Comparatively, ADC Therapeutics has a beta of 1.87, indicating that its stock price is 87% more volatile than the broader market.

Tectonic Therapeutic currently has a consensus price target of $79.40, indicating a potential upside of 131.22%. ADC Therapeutics has a consensus price target of $6.25, indicating a potential upside of 404.44%. Given ADC Therapeutics' higher possible upside, analysts clearly believe ADC Therapeutics is more favorable than Tectonic Therapeutic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tectonic Therapeutic	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00
ADC Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Tectonic Therapeutic beats ADC Therapeutics on 11 of the 16 factors compared between the two stocks.

How does ADC Therapeutics compare to 4D Molecular Therapeutics?

ADC Therapeutics (NYSE:ADCT) and 4D Molecular Therapeutics (NASDAQ:FDMT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, media sentiment, institutional ownership, dividends, profitability and risk.

ADC Therapeutics has a net margin of -173.02% compared to 4D Molecular Therapeutics' net margin of -182.34%. ADC Therapeutics' return on equity of 0.00% beat 4D Molecular Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADC Therapeutics	-173.02%	N/A	-44.70%
4D Molecular Therapeutics	-182.34%	-36.83%	-32.55%

4D Molecular Therapeutics has higher revenue and earnings than ADC Therapeutics. 4D Molecular Therapeutics is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADC Therapeutics	$81.36M	1.94	-$142.62M	-$1.05	N/A
4D Molecular Therapeutics	$85.21M	6.93	-$140.11M	-$2.57	N/A

In the previous week, 4D Molecular Therapeutics had 1 more articles in the media than ADC Therapeutics. MarketBeat recorded 2 mentions for 4D Molecular Therapeutics and 1 mentions for ADC Therapeutics. 4D Molecular Therapeutics' average media sentiment score of 0.94 beat ADC Therapeutics' score of 0.00 indicating that 4D Molecular Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADC Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
4D Molecular Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

41.1% of ADC Therapeutics shares are held by institutional investors. Comparatively, 99.3% of 4D Molecular Therapeutics shares are held by institutional investors. 5.4% of ADC Therapeutics shares are held by insiders. Comparatively, 7.9% of 4D Molecular Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

ADC Therapeutics has a beta of 1.87, meaning that its stock price is 87% more volatile than the broader market. Comparatively, 4D Molecular Therapeutics has a beta of 2.7, meaning that its stock price is 170% more volatile than the broader market.

ADC Therapeutics presently has a consensus price target of $6.25, indicating a potential upside of 404.44%. 4D Molecular Therapeutics has a consensus price target of $29.88, indicating a potential upside of 164.38%. Given ADC Therapeutics' higher probable upside, research analysts clearly believe ADC Therapeutics is more favorable than 4D Molecular Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADC Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
4D Molecular Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

4D Molecular Therapeutics beats ADC Therapeutics on 11 of the 16 factors compared between the two stocks.

How does ADC Therapeutics compare to Monopar Therapeutics?

Monopar Therapeutics (NASDAQ:MNPR) and ADC Therapeutics (NYSE:ADCT) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, dividends, risk, media sentiment, profitability, analyst recommendations and institutional ownership.

Monopar Therapeutics has higher earnings, but lower revenue than ADC Therapeutics. Monopar Therapeutics is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monopar Therapeutics	N/A	N/A	-$13.72M	-$1.90	N/A
ADC Therapeutics	$81.36M	1.94	-$142.62M	-$1.05	N/A

Monopar Therapeutics has a net margin of 0.00% compared to ADC Therapeutics' net margin of -173.02%. ADC Therapeutics' return on equity of 0.00% beat Monopar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monopar Therapeutics	N/A	-12.84%	-12.57%
ADC Therapeutics	-173.02%	N/A	-44.70%

Monopar Therapeutics has a beta of 1.46, suggesting that its stock price is 46% more volatile than the broader market. Comparatively, ADC Therapeutics has a beta of 1.87, suggesting that its stock price is 87% more volatile than the broader market.

Monopar Therapeutics presently has a consensus price target of $108.75, suggesting a potential upside of 5.25%. ADC Therapeutics has a consensus price target of $6.25, suggesting a potential upside of 404.44%. Given ADC Therapeutics' higher probable upside, analysts plainly believe ADC Therapeutics is more favorable than Monopar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monopar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
ADC Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Monopar Therapeutics had 2 more articles in the media than ADC Therapeutics. MarketBeat recorded 3 mentions for Monopar Therapeutics and 1 mentions for ADC Therapeutics. Monopar Therapeutics' average media sentiment score of 0.46 beat ADC Therapeutics' score of 0.00 indicating that Monopar Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Monopar Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
ADC Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

1.8% of Monopar Therapeutics shares are owned by institutional investors. Comparatively, 41.1% of ADC Therapeutics shares are owned by institutional investors. 9.7% of Monopar Therapeutics shares are owned by insiders. Comparatively, 5.4% of ADC Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Monopar Therapeutics beats ADC Therapeutics on 9 of the 16 factors compared between the two stocks.

How does ADC Therapeutics compare to Relmada Therapeutics?

ADC Therapeutics (NYSE:ADCT) and Relmada Therapeutics (NASDAQ:RLMD) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, media sentiment, dividends, analyst recommendations, risk and institutional ownership.

Relmada Therapeutics has a net margin of 0.00% compared to ADC Therapeutics' net margin of -173.02%. ADC Therapeutics' return on equity of 0.00% beat Relmada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADC Therapeutics	-173.02%	N/A	-44.70%
Relmada Therapeutics	N/A	-71.22%	-64.46%

In the previous week, Relmada Therapeutics had 1 more articles in the media than ADC Therapeutics. MarketBeat recorded 2 mentions for Relmada Therapeutics and 1 mentions for ADC Therapeutics. Relmada Therapeutics' average media sentiment score of 0.44 beat ADC Therapeutics' score of 0.00 indicating that Relmada Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
ADC Therapeutics	Neutral
Relmada Therapeutics	Neutral

41.1% of ADC Therapeutics shares are owned by institutional investors. Comparatively, 45.2% of Relmada Therapeutics shares are owned by institutional investors. 5.4% of ADC Therapeutics shares are owned by company insiders. Comparatively, 14.5% of Relmada Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Relmada Therapeutics has lower revenue, but higher earnings than ADC Therapeutics. Relmada Therapeutics is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADC Therapeutics	$81.36M	1.94	-$142.62M	-$1.05	N/A
Relmada Therapeutics	N/A	N/A	-$57.38M	-$1.09	N/A

ADC Therapeutics presently has a consensus price target of $6.25, suggesting a potential upside of 404.44%. Relmada Therapeutics has a consensus price target of $12.00, suggesting a potential upside of 86.05%. Given ADC Therapeutics' higher possible upside, equities analysts plainly believe ADC Therapeutics is more favorable than Relmada Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADC Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

ADC Therapeutics has a beta of 1.87, suggesting that its stock price is 87% more volatile than the broader market. Comparatively, Relmada Therapeutics has a beta of 0.41, suggesting that its stock price is 59% less volatile than the broader market.

Summary

Relmada Therapeutics beats ADC Therapeutics on 9 of the 16 factors compared between the two stocks.

How does ADC Therapeutics compare to CytomX Therapeutics?

CytomX Therapeutics (NASDAQ:CTMX) and ADC Therapeutics (NYSE:ADCT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings, media sentiment and risk.

CytomX Therapeutics has higher earnings, but lower revenue than ADC Therapeutics. CytomX Therapeutics is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CytomX Therapeutics	$76.20M	8.26	-$17.37M	-$0.41	N/A
ADC Therapeutics	$81.36M	1.94	-$142.62M	-$1.05	N/A

67.8% of CytomX Therapeutics shares are owned by institutional investors. Comparatively, 41.1% of ADC Therapeutics shares are owned by institutional investors. 3.8% of CytomX Therapeutics shares are owned by company insiders. Comparatively, 5.4% of ADC Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

CytomX Therapeutics has a net margin of -166.40% compared to ADC Therapeutics' net margin of -173.02%. ADC Therapeutics' return on equity of 0.00% beat CytomX Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CytomX Therapeutics	-166.40%	-36.61%	-28.02%
ADC Therapeutics	-173.02%	N/A	-44.70%

In the previous week, CytomX Therapeutics had 3 more articles in the media than ADC Therapeutics. MarketBeat recorded 4 mentions for CytomX Therapeutics and 1 mentions for ADC Therapeutics. CytomX Therapeutics' average media sentiment score of 1.18 beat ADC Therapeutics' score of 0.00 indicating that CytomX Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CytomX Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ADC Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CytomX Therapeutics has a beta of 2.08, suggesting that its stock price is 108% more volatile than the broader market. Comparatively, ADC Therapeutics has a beta of 1.87, suggesting that its stock price is 87% more volatile than the broader market.

CytomX Therapeutics presently has a consensus target price of $12.10, suggesting a potential upside of 227.03%. ADC Therapeutics has a consensus target price of $6.25, suggesting a potential upside of 404.44%. Given ADC Therapeutics' higher possible upside, analysts plainly believe ADC Therapeutics is more favorable than CytomX Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CytomX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91
ADC Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

CytomX Therapeutics beats ADC Therapeutics on 12 of the 17 factors compared between the two stocks.

Get ADC Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ADCT vs. The Competition

Export

Metric	ADC Therapeutics	MED Industry	Medical Sector	NYSE Exchange
Market Cap	$164.08M	$3.71B	$7.05B	$23.46B
Dividend Yield	N/A	2.20%	2.68%	4.02%
P/E Ratio	-1.18	20.85	27.12	31.08
Price / Sales	1.94	314.01	587.25	19.77
Price / Cash	N/A	61.98	29.22	18.64
Price / Book	-0.83	8.49	10.89	4.77
Net Income	-$142.62M	$23.83M	$3.58B	$1.06B
7 Day Performance	-9.23%	-3.56%	-2.11%	-0.23%
1 Month Performance	17.55%	6.31%	3.28%	-0.11%
1 Year Performance	-62.95%	48.30%	26.33%	16.46%

ADC Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ADCT ADC Therapeutics	2.344 of 5 stars	$1.24 -4.0%	$6.25 +404.4%	-60.8%	$164.08M	$81.36M	N/A	310	Gap Down
TECX Tectonic Therapeutic	2.8784 of 5 stars	$35.91 +2.0%	$79.40 +121.1%	+51.7%	$677.62M	N/A	N/A	120	News Coverage
FDMT 4D Molecular Therapeutics	1.7984 of 5 stars	$12.74 +0.2%	$29.88 +134.4%	+164.0%	$665.84M	$85.21M	N/A	120
MNPR Monopar Therapeutics	1.1313 of 5 stars	$97.44 +0.3%	$108.75 +11.6%	+180.3%	$655.90M	N/A	N/A	10	Analyst Downgrade
RLMD Relmada Therapeutics	2.1348 of 5 stars	$6.22 -1.8%	$12.00 +93.1%	+957.4%	$651.26M	N/A	N/A	10	Short Interest Increase

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ADCT) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ADC Therapeutics (ADCT) Competitors

ADCT vs. TECX, FDMT, MNPR, RLMD, and CTMX

How does ADC Therapeutics compare to Tectonic Therapeutic?

Summary

How does ADC Therapeutics compare to 4D Molecular Therapeutics?

Summary

How does ADC Therapeutics compare to Monopar Therapeutics?

Summary

How does ADC Therapeutics compare to Relmada Therapeutics?

Summary

How does ADC Therapeutics compare to CytomX Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADCT vs. The Competition

ADC Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ADC Therapeutics (ADCT) Competitors

ADCT vs. TECX, FDMT, MNPR, RLMD, and CTMX

How does ADC Therapeutics compare to Tectonic Therapeutic?

Which has stronger earnings & valuation, TECX or ADCT?

Is TECX or ADCT more profitable?

Does the media favor TECX or ADCT?

Do institutionals and insiders believe in TECX or ADCT?

Which has more risk and volatility, TECX or ADCT?

Do analysts rate TECX or ADCT?

Summary

How does ADC Therapeutics compare to 4D Molecular Therapeutics?

Is ADCT or FDMT more profitable?

Which has better earnings and valuation, ADCT or FDMT?

Does the media prefer ADCT or FDMT?

Do institutionals and insiders hold more shares of ADCT or FDMT?

Which has more volatility & risk, ADCT or FDMT?

Do analysts rate ADCT or FDMT?

Summary

How does ADC Therapeutics compare to Monopar Therapeutics?

Which has stronger earnings and valuation, MNPR or ADCT?

Is MNPR or ADCT more profitable?

Which has more volatility and risk, MNPR or ADCT?

Do analysts recommend MNPR or ADCT?

Does the media favor MNPR or ADCT?

Do institutionals & insiders hold more shares of MNPR or ADCT?

Summary

How does ADC Therapeutics compare to Relmada Therapeutics?

Is ADCT or RLMD more profitable?

Does the media refer more to ADCT or RLMD?

Do institutionals and insiders hold more shares of ADCT or RLMD?

Which has better valuation and earnings, ADCT or RLMD?

Do analysts recommend ADCT or RLMD?

Which has more risk & volatility, ADCT or RLMD?

Summary

How does ADC Therapeutics compare to CytomX Therapeutics?

Which has preferable valuation & earnings, CTMX or ADCT?

Do institutionals & insiders have more ownership in CTMX or ADCT?

Is CTMX or ADCT more profitable?

Does the media prefer CTMX or ADCT?

Which has more risk & volatility, CTMX or ADCT?

Do analysts rate CTMX or ADCT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADCT vs. The Competition

ADC Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools